Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

30.30
-1.4500-4.57%
Post-market: 30.300.00000.00%16:34 EDT
Volume:904.82K
Turnover:27.65M
Market Cap:2.01B
PE:-7.77
High:31.75
Open:31.29
Low:30.00
Close:31.75
52wk High:34.52
52wk Low:14.40
Shares:66.45M
Float Shares:53.21M
Volume Ratio:0.64
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9000
EPS(LYR):-3.9000
ROE:-40.62%
ROA:-26.12%
PB:3.82
PE(LYR):-7.77

Loading ...

Celldex Therapeutics Inc : Morgan Stanley Raises Target Price to $44.00 From $43.00

THOMSON REUTERS
·
Feb 26

Barclays Reaffirms Their Sell Rating on Celldex (CLDX)

TIPRANKS
·
Feb 26

Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)

Reuters
·
Feb 26

Celldex Therapeutics Q4 EPS USD -1.22 VS. Ibes Estimate USD -1.01

THOMSON REUTERS
·
Feb 26

Celldex Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk

Dow Jones
·
Feb 26

Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early

Dow Jones
·
Feb 25

Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)

TIPRANKS
·
Feb 25

BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria

Reuters
·
Feb 25

Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria

THOMSON REUTERS
·
Feb 25

Celldex Therapeutics Inc - Topline Data Expected Q4 2026

THOMSON REUTERS
·
Feb 25

Anixa Biosciences to Spotlight Lira-cel Phase 1 Trial at SCTR Institute 2026 Retreat

Reuters
·
Feb 23

Celldex to Present Phase 2 Barzolvolimab Data at AAAAI Annual Meeting

Reuters
·
Feb 23

Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil

Reuters
·
Feb 09

Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses

Simply Wall St.
·
Feb 04

Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX

TIPRANKS
·
Jan 22

Celldex (CLDX) Gets a Buy from Mizuho Securities

TIPRANKS
·
Jan 09

Barclays Remains a Sell on Celldex (CLDX)

TIPRANKS
·
Jan 09

Bayer And Souffle Therapeutics Partner Up To Advance Cell-Specific Heart-Targeted siRNA Therapy

Reuters
·
Jan 08

Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?

Simply Wall St.
·
Dec 22, 2025

Celldex Therapeutics Is Maintained at Underweight by Barclays

Dow Jones
·
Dec 18, 2025